Cell-free PAI-1/uPA complex formation and cleavage
Biochemical assay · Full-length stabilized recombinant human PAI-1 (14-1b) and human high-molecular-weight uPA in a cell-free assay. [1]
Tiplaxtinin reduced PAI-1/uPA complex bands and promoted a lower-molecular-weight PAI-1 cleavage product. This supports substrate-like behavior under the tested conditions; it is not a direct binding or potency determination.
| Endpoint | Reported result | Reference |
|---|---|---|
| PAI-1/uPA complex formation and PAI-1 cleavage | Qualitative SDS-PAGE pattern Complex bands decreased and cleaved PAI-1 appeared as tiplaxtinin increased; qualitative gel result, no numerical effect size. | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- 0, 10, 20, 40 and 80 µM tiplaxtinin (Fig. 2A lane labels); 500 nmol/L FL-PAI-1 and 500 nM uPA (Section 2.11).
- Exposure duration
- 15 min tiplaxtinin/PAI-1 preincubation, followed by 5 min with uPA at 37°C.
- Method
- SDS-PAGE analysis after incubation in HEPES/NaCl/Tween-20 buffer.
- Vehicle
- Vehicle-alone comparator; vehicle composition for this cell-free assay not specified in Section 2.11.
- Co-treatment
- uPA is the assay reactant, not a co-therapy.
- Reported limits
- Preincubation temperature, replicate count and band-density quantification are not reported for Fig. 2A. No IC50 inferred.
Methods and source locations
Compound reported in the paper: Tiplaxtinin (PAI-039); Compound label in the paper: TPX
Evidence for the named research compound in the specified preparation/model; not validation of an Adooq lot or equivalence among salts.
Experimental Procedures 2.2, 2.11; Results 3.2; Fig. 2A and caption
PAI-1/uPA complex formation and PAI-1 cleavage: Comparison with uPA-alone, FL-PAI-1-alone and zero-tiplaxtinin reaction lanes. — Fig. 2A lane labels and gel; Results 3.2; Section 2.11